Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103428 · ClinicalTrials.gov registry record · Phase 1
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase 1 study, sponsored by Cell Genesys.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00103428: Clinical Trial Phase 1 study, sponsored by Cell Genesys.
NCT00103428 is a Phase 1 study that was terminated before completion, run by Cell Genesys. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103428, a Phase 1 study, was terminated before completion, sponsored by Cell Genesys.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy. All patients will receive docetaxel. In the dose escalation phase of the study, patients will receive treatment intravenously with CG7870 at one of up to four dose levels. In the Phase 2 portion of this study, additional patients will be added at the maximum tolerated dose that is determined in Phase 1.
Interventions
- BIOLOGICAL CG7870
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103428
The ClinicalTrials.gov registry entry for NCT00103428 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CG7870 is the first listed.
NCT00103428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103428 about?
NCT00103428 is a clinical study titled "Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer". V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy. All patients will receive docetaxel. In the dose escalation phase of the study, patients will receive treatment intravenously with CG7870...
What is the current status of trial NCT00103428?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2004-08.
What interventions are being tested in trial NCT00103428?
The interventions under investigation include: CG7870 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00103428?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.